Skip to content
X

Neon Therapeutics
Field: Cancer immunotherapy
Stage: Pre-Clinical
Status: Public
CEO: Hugh O’Dowd
Neon Therapeutics is an immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer, building on years of research at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute. Neon’s lead program, NEO-PTC-01, is a personal neoantigen-based T cell therapy that will be tested first in melanoma and ovarian cancer.
Press Releases
-
10Nov
-
15Jul
-
01Apr
-
09Dec
-
23Oct
-
27Jun
-
17Jun
-
03Jun
-
03Jun
-
09May
-
15Apr
-
10Dec
-
06Dec
-
01Nov
2019
2018
2017